Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 9, Number 6—June 2003

Dispatch

Poor Potential Coverage for 7-Valent Pneumococcal Conjugate Vaccine, Malawi

Stephen B. Gordon*Comments to Author , Stonard Kanyanda*, Amanda L. Walsh*, Kristy Goddard*, Mas Chaponda†, Victoria Atkinson†, Wakisa Mulwafu†, Elizabeth M. Molyneux†, Ed E. Zijlstra†, Malcolm E. Molyneux*, and Steve M. Graham*
Author affiliations: *Wellcome Trust Research Laboratories, University of Malawi, Liverpool, U.K.; †University of Malawi College of Medicine, Blantyre, Malawi

Main Article

Figure

The cumulative percentage of all pneumococcal isolates plotted by source (see key). Serogroups covered by the 7-valent vaccine are plotted to the left of the heavy vertical line, and the potential 9-valent coverage is illustrated by the dotted vertical line.

Figure. The cumulative percentage of all pneumococcal isolates plotted by source (see key). Serogroups covered by the 7-valent vaccine are plotted to the left of the heavy vertical line, and the potential 9-valent coverage is illustrated by the dotted vertical line.

Main Article

TOP